All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
8 results for "Cancer" and "Prostate and Urologic Cancers" and "Multiple Myeloma"
A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Protocol No
NOVARTIS-CWVT078A12101
Sub Category
Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of REGN5459 and to find out what is the best dose of REGN5459 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5459 can treat your cancer.
Protocol No
REGENERON-R5459-ONC-1888
Sub Category
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
The purpose of this study is to find a safe and tolerable dose of either JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] when administered in combination with Daratumumab subcutaneous injection (Dara SC) in patients with multiple myeloma. A dose is how much of a drug you take at one time. This study will also look at how JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC, known as combination 1 or JNJ-64007957 [anti-BCMAxCD3] and Dara SC, known as combination 2 act in your body, as well as whether each of the combination of drugs will treat your multiple myeloma.
1. Combination 1: JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC
2. Combination 2: JNJ-64007957 [anti-BCMAxCD3] and Dara SC
Another purpose of this study is to find out how long JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] in combination with Dara SC stay in and act on your body. This is measured by blood tests.
1. Combination 1: JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC
2. Combination 2: JNJ-64007957 [anti-BCMAxCD3] and Dara SC
Another purpose of this study is to find out how long JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] in combination with Dara SC stay in and act on your body. This is measured by blood tests.
Protocol No
JANSSEN-64407564MMY1002
Sub Category
A Phase 1/2, Dose Escalation Safety And Tolerability Study Of AO-176 As Monotherapy And In Combination With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma
You are being asked to participate in this study because you have multiple myeloma and your disease has returned after receiving treatment (recurrent disease) or it is no longer responding to your most recent treatment (refractory disease). Arch Oncology, the sponsor of the clinical trial, is studying AO-176 by itself or in combination with either dexamethasone or with both dexamethasone and bortezomib, as a potential treatment for people with recurrent or refractory multiple myeloma
Protocol No
ARCH-AO-176-102
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol No
TENEOBIO-TNB-383B
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
An Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of SAR442085 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of the escalation phase is to determine the maximum tolerated dose and to determine the recommended dose that is to be used in the expansion phase (Part B) of the study. In the escalation phase, the study will determine the best dose level which will minimize the risk of side effects during testing.
Protocol No
SANOFI-TED16132